WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319938

CAS#: 43200-80-2

Description: NOTE: Zopiclone has been discontinued | Zopiclone is a nonbenzodiazepine hypnotic agent used in the treatment of insomnia. It is a cyclopyrrolone, which increases the normal transmission of the neurotransmitter GABA in the central nervous system, as benzodiazepines do, but in a different way. As zopiclone is sedating, it is marketed as a sleeping pill. It works by causing a depression or tranquilization of the central nervous system.

Chemical Structure

CAS# 43200-80-2

Theoretical Analysis

MedKoo Cat#: 319938
Name: Zopiclone
CAS#: 43200-80-2
Chemical Formula: C17H17ClN6O3
Exact Mass: 388.1051
Molecular Weight: 388.812
Elemental Analysis: C, 52.52; H, 4.41; Cl, 9.12; N, 21.62; O, 12.34

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: RP-27267; RP27267; RP 27267; BRN 0768704; Zopiclone. brand names Zimovane and Imovane.

IUPAC/Chemical Name: 6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate


InChi Code: InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 388.812 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Curreen M, Lidmila J. Zopiclone: Is there cause for concern in addiction services and general practice? Int J Risk Saf Med. 2014;26(4):183-9. doi: 10.3233/JRS-140633. Review. PubMed PMID: 25420760.

2: Stranks EK, Crowe SF. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol. 2014;36(7):691-700. doi: 10.1080/13803395.2014.928268. Epub 2014 Jun 16. Review. PubMed PMID: 24931450.

3: Chan TY. Zopiclone induced methemoglobinemia and hemolytic anemia. Int J Clin Pharmacol Ther. 2014 May;52(5):402-6. doi: 10.5414/CP202082. Review. PubMed PMID: 24569128.

4: Verster JC, Spence DW, Shahid A, Pandi-Perumal SR, Roth T. Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. Curr Drug Saf. 2011 Sep 1;6(4):209-18. Review. PubMed PMID: 22129315.

5: Eszopiclone: esopiclone, estorra, S-zopiclone, zopiclone--Sepracor. Drugs R D. 2005;6(2):111-5. Review. PubMed PMID: 15777104.

6: Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet. 2004;43(4):227-38. Review. PubMed PMID: 15005637.

7: Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003 Oct;98(10):1371-8. Review. PubMed PMID: 14519173.

8: Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs. 2003;17(7):513-32. Review. PubMed PMID: 12751920.

9: Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):261-82. Review. PubMed PMID: 12608888.

10: Montplaisir J, Hawa R, Moller H, Morin C, Fortin M, Matte J, Reinish L, Shapiro CM. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol. 2003 Jan;18(1):29-38. Review. PubMed PMID: 12532313.

11: Georgiev V. (S)-Zopiclone Sepracor. Curr Opin Investig Drugs. 2001 Feb;2(2):271-3. Review. PubMed PMID: 11816843.

12: Hajak G. A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience. Drug Saf. 1999 Dec;21(6):457-69. Review. PubMed PMID: 10612270.

13: Bramness JG, Olsen H. [Adverse effects of zopiclone]. Tidsskr Nor Laegeforen. 1998 May 20;118(13):2029-32. Review. Norwegian. PubMed PMID: 9656789.

14: Katsunuma H, Shimizu T, Ogawa K, Kubo H, Ishida H, Yoshihama A. Treatment of insomnia by concomitant therapy with Zopiclone and Aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci. 1998 Apr;52(2):198-200. Review. PubMed PMID: 9628149.

15: Noble S, Langtry HD, Lamb HM. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs. 1998 Feb;55(2):277-302. Review. PubMed PMID: 9506247.

16: Lader M. Zopiclone: is there any dependence and abuse potential? J Neurol. 1997 Apr;244(4 Suppl 1):S18-22. Review. PubMed PMID: 9112585.

17: Hajak G, Rodenbeck A. Clinical management of patients with insomnia. The role of zopiclone. Pharmacoeconomics. 1996;10 Suppl 1:29-38. Review. PubMed PMID: 10163425.

18: Fernandez C, Martin C, Gimenez F, Farinotti R. Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet. 1995 Dec;29(6):431-41. Review. PubMed PMID: 8787948.

19: Wadworth AN, McTavish D. Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging. 1993 Sep-Oct;3(5):441-59. Review. Erratum in: Drugs Aging 1994 Jan;4(1):62. PubMed PMID: 8241608.

20: Stutzmann JM, Delahaye C, Allain H. [Zopiclone. Data of experimental pharmacology and clinical use]. Therapie. 1993 Jan-Feb;48(1):33-42. Review. French. PubMed PMID: 8356543.